JPMorgan Chase & Co. Has $7.47 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• JPMorgan Chase & Co. boosted its stake in Kiniksa by 42.3% in Q3 to 192,456 shares, worth about $7.47 million and representing roughly 0.25% of the company.
• Insiders have been net sellers: executives including CFO Mark Ragosa and Director Barry Quart sold shares, with insiders selling 48,605 shares (~$2.12M) in the last three months, though insiders still hold about 53.48% of the stock.
• Analyst and financial snapshot: the stock carries a consensus "Moderate Buy" rating with an average target of $55.29; Kiniksa reported revenue up 65% year-over-year but missed EPS at $0.17 versus $0.29, and has a market cap of ~$3.5 billion.

JPMorgan Chase & Co. boosted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 42.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,456 shares of the company's stock after buying an additional 57,174 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.25% of Kiniksa Pharmaceuticals International worth $7,473,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. GSA Capital Partners LLP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 281.9% during the third quarter. GSA Capital Partners LLP now owns 77,984 shares of the company's stock valued at $3,028,000 after acquiring an additional 57,566 shares during the period. Aberdeen Group plc bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth about $6,163,000. Fisher Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 176.1% in the 3rd quarter. Fisher Asset Management LLC now owns 282,288 shares of the company's stock worth $10,961,000 after purchasing an additional 180,029 shares during the last quarter. Essex Investment Management Co. LLC increased its position in shares of Kiniksa Pharmaceuticals International by 44.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company's stock worth $9,603,000 after purchasing an additional 75,864 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth about $1,480,000. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KNSA shares. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a "buy" rating and a $62.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of "Moderate Buy" and an average target price of $55.29.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 17,845 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the transaction, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Barry D. Quart sold 2,690 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at $564,570. The trade was a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 48,605 shares of company stock valued at $2,122,646. 53.48% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Stock Down 0.1%

Shares of NASDAQ:KNSA opened at $45.70 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.25 and a 12 month high of $49.12. The company's 50-day moving average price is $45.01 and its two-hundred day moving average price is $41.59. The firm has a market cap of $3.50 billion, a P/E ratio of 61.76 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same period in the prior year, the firm posted ($0.12) earnings per share. The company's revenue was up 65.0% on a year-over-year basis. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.